Physician profile
Luis A Alvarez
NPI 1861412587
$7,867.04
in general payments reported to CMS, 2019-2025
45 companies · $1,399 in 2025
The $1,399 reported for 2025 was more than what 89% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $1,156 · 2021: $1,016 · 2022: $1,165 · 2023: $1,380 · 2024: $1,395 · 2025: $1,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,053 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,053.08 |
| Education | $121.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,962.37 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $612.71 | 2019-2024 | |
| Exact Sciences Corporation | $540.05 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $461.75 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $428.54 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $382.58 | 2021-2024 | Rexulti |
| Astellas Pharma US INC | $319.77 | 2020-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $274.13 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.23 | 2020-2025 | Jardiance |
| Lundbeck LLC | $237.37 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $214.29 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $213.47 | 2019-2022 | |
| Abbott Laboratories | $189.75 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Atricure, INC. | $166.59 | 2022 | |
| Glaxosmithkline, LLC. | $162.95 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.